BC Week In Review | Feb 8, 2016
Clinical News

EscharEx: Phase II data

Top-line data from a single-blind, Israeli and European Phase II trial in 73 patients showed that EscharEx met the primary endpoint of a greater incidence of complete debridement at the end of the debridement period...
BC Week In Review | Sep 7, 2015
Clinical News

EscharEx: Completed Phase II enrollment

MediWound completed enrollment of 73 patients in the double-blind, vehicle-controlled, Israeli and European Phase II trial evaluating EscharEx. The wounds include diabetic foot ulcers, venous ulcers and postsurgical or traumatic hard-to-heal wounds. MediWound Ltd. (NASDAQ:MDWD),...
BC Week In Review | Jun 2, 2014
Clinical News

EscharEx: Phase II started

MediWound began a double-blind, vehicle-controlled, Israeli Phase II trial to evaluate EscharEx in about 72 patients with chronic and other hard-to-heal wounds, including diabetic foot ulcers, venous ulcers and post-surgical or traumatic hard-to-heal wounds. MediWound...
Items per page:
1 - 3 of 3